HONG KONG, Aug. 11, 2021 /PRNewswire/ Insilico Medicine, a global leader in end-to-end AI-powered drug discovery, today announced the appointment of Steven Galson, MD, MPH as the independent
Insilico s Chemistry42 AI system integrated into UCB s drug discovery programs
Insilico Medicine announces that UCB will integrate its AI-based system for de novo molecular design, Chemistry42, into its drug discovery programs
HONG KONG, March 9, 2021 /PRNewswire/ Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico s Chemistry42 into UCB s internal drug discovery pipeline. UCB s early adoption of Insilico Medicine s proprietary technology will provide UCB s scientists with the ability to design novel hit compounds that satisfy multiple predefined parameters rapidly and streamline lead optimization. With the Chemistry42 platform, UCB scientists will also reduce the efforts and costs typically associated with the design, testing and commercialization of new drugs. Chemistry42 v1.0 will be customized and deployed on UCB s cloud-based supercomputing infrastructure.
Chinese firm Insilico to test AI-developed drug By Cheng Yu | chinadaily.com.cn | Updated: 2021-03-05 14:26 Share [Photo/IC]
Insilico Medicine, a Chinese investors-backed company that uses artificial intelligence to develop new drugs, said that its chemical compound candidate is likely to enter into clinical trials by the end of this year, according to its top executives. We expect our chemical compound candidate to start its first clinic trial by the end of the end before the second and third trials, said Ren Feng, chief science officer at Insilico Medicine. (Once finished), it will be the first time that the world uses AI to find new targets, discover new compounds, and makes into the clinical period, which will be a milestone, Ren said.
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence
HONG KONG, Feb. 24, 2021 /PRNewswire/ Insilico Medicine has demonstrated a breakthrough in Artificial Intelligence ( AI ) and drug discovery - linking together generative chemistry and biology for the first time - to discover a novel preclinical candidate addressing idiopathic pulmonary fibrosis
( IPF ) and be validated with multiple human cell and animal model experiments. Often found implicated in a wide range of diseases and multiple organs such as lung, liver and kidney, IPF addresses a very broad medical need that affects hundreds of thousands of individuals worldwide.